Posts for Ticker ‘ALTH’

Major Secondary Offerings Keep Coming (ALTH, ATAX, ARYX, APPY, GRS, LINE, SGMO, CAR)

Money Stack ImageWe are seeing more and more waves of secondary offerings continue to hit the Street since the stock market has held up. Many stocks are close to near-term highs and it seems they are raising cash in case the opportunity goes away.  Allos Therapeutics, Inc. (NASDAQ: ALTH), America First Tax Exempt Investors, L.P. (Nasdaq: ATAX), ARYx Therapeutics, Inc. (NASDAQ: ARYX), AspenBio Pharma Inc. (NASDAQ: APPY), Gammon Gold, Inc. (NYSE: GRS), LINN Energy, LLC (NASDAQ: LINE), and Sangamo BioSciences, Inc. (Nasdaq: SGMO) have all priced secondary offerings.  Avis Budget Group, Inc. (NYSE: CAR) is one of the pending offerings.
Read More »

Posted on: October 7, 2009 – 11:09 am in Secondary Offering, , , , , , , ,

Stocks Trading On Heavy Volume Or Price (RIMM)(TIBX)(UCBI)(ALTH)

According to the watch list at Volume Spike Investor several stocks are making large moves before the open.

The most substantial activity is in RIM (RIMM)   Tibco (TIBX)  United Community Banks (UCBI)  and Allos (ALTH).

Douglas A. McIntyre

Posted on: September 25, 2009 – 8:35 am in Pre-Market Activity, , , ,

The Unusual Suspects (ATVI, AIG, ALTH, TREE, GOOG, PAY, EXPO, WIRE, AXYS)

bull-and-bear-image2We have almost a whole new slate of stocks in this week’s round of “The Unusual Suspects” for key stocks traders need to keep an eye on for the week ahead.  Activision Blizzard Inc. (NASDAQ: ATVI) was singled out by Barron’s.  We ran a bit noting $100 as a possible target for American International Group Inc. (NYSE: AIG), and let’s just say that it was widely read.  Allos Therapeutics Inc. (NASDAQ: ALTH) has a key FDA ruling this coming week.  Tree.com, Inc. (NASDAQ: TREE) may have its model crushed by none other than Google Inc. (NASDAQ: GOOG).  And troubled VeriFone Holdings, Inc. (NYSE: PAY) has earnings due this coming week, right at a key stock inflection point.  Exponent Inc. (NASDAQ: EXPO) and Encore Wire Corp. (NASDAQ: WIRE) are S&P index additions as new entrants.  Axsys Technologies Inc. (NASDAQ: AXYS) also has a shareholder proxy date this week, and some think a higher buyout price may be in the works.  We have run key details and previews for all of these to watch in the coming week.

Read More »

Posted on: August 29, 2009 – 12:00 pm in Activist Investor, Analyst Calls, Biotech, Calendar, Charts, Earnings, Editor's Picks, FDA, Financial Stocks, Index, Internet, Mergers and Buy Outs, Rumors, Technology Companies, The Week, Video Games, , , , , , , , ,

Full 2009 ASCO Cancer & Oncology Primer (ABII, AEZS, ALTH, AMGN, APPA, ARQL, BMY, CLDX, CELG, CTIC, CGRB, LLY, EXEL, GHDX, GSK, IMGN, MEDX, MDVN, MITI, OGXI, OSIP, PPHM, PFE, ROSG, SNTA, TRBN, ZIOP, ZGEN)

We have compiled an updated lengthy 2009 American Society of Clinical Oncology, or ASCO, document showing many company cancer data presentations slated to start this weekend.   This is broken down in drug and biotech companies with share values, ranges, and recent developments for the following drug and biotech companies:  Abraxis BioScience, Inc. (NASDAQ:ABII), AEterna Zentaris Inc. (NASDAQ: AEZS), Allos Therapeutics, Inc. (NASDAQ: ALTH), Amgen Inc. (NASDAQ: AMGN), A.P. Pharma, Inc. (Nasdaq: APPA), Arqule Inc. (NASDAQ: ARQL), Bristol-Myers Squibb (NYSE: BMY), Celldex Therapeutics (NASDAQ: CLDX), Celgene Corporation (NASDAQ: CELG), Cell Therapeutics (NASDAQ: CTIC), Cougar Biotechnology, Inc. (NASDAQ: CGRB), Eli Lilly and Company (NYSE: LLY), Exelixis (NASDAQ: EXEL), Genomic Health, Inc. (NASDAQ: GHDX), GlaxoSmithKline (NYSE: GSK) , Immunogen (NASDAQ: IMGN), Medarex (NASDAQ: MEDX), Medivation, Inc. (NASDAQ: MDVN), Micromet, Inc. (NASDAQ: MITI), OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), OSI Pharmaceuticals (NASDAQ: OSIP), Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), Pfizer Inc. (NYSE: PFE), Rosetta Genomics (NASDAQ:ROSG), Synta Pharmaceuticals (NASDAQ: SNTA), Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN), ZIOPHARM Oncology (NASDAQ: ZIOP), and ZymoGenetics, Inc. (NASDAQ: ZGEN).

The full presentation can be seen at BioHealthInvestor.com.

JON C. OGG
May 27, 2009

Posted on: May 27, 2009 – 1:34 pm in Biotech, Drug companies, FDA, Medical, Pharmaceuticals, , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Previewing 2009 ASCO Abstracts (ABII, ALTH, ARQL, CLDX, CTIC, CGRB, LLY, EXEL, GHDX, GSK, IMGN, MEDX, MDVN, OGXI, OSIP, PPHM, PFE, SNTA, ZIOP)

We are just about to get the first round of abstracts from companies presenting data at this year’s American Society of Clinical Oncology meeting for 2009.  At BioHealthInvestor.com we compiled a brief summary for companies such as Abraxis BioScience, Inc. (NASDAQ:ABII), Allos Therapeutics, Inc. (NASDAQ: ALTH), Arqule Inc. (NASDAQ: ARQL), Celldex Therapeutics (NASDAQ: CLDX), Cell Therapeutics (NASDAQ: CTIC), Cougar Biotechnology, Inc. (NASDAQ: CGRB), Eli Lilly and Company (NYSE:  LLY), Exelixis (NASDAQ: EXEL), Genomic Health, Inc. (NASDAQ: GHDX), GlaxoSmithKline (NYSE: GSK) , Immunogen (NASDAQ: IMGN), Medarex (NASDAQ: MEDX), Medivation, Inc. (NASDAQ: MDVN), OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), OSI Pharmaceuticals (NASDAQ: OSIP), Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), Pfizer Inc. (NYSE: PFE), Synta Pharmaceuticals (NASDAQ: SNTA), and ZIOPHARM Oncology (NASDAQ: ZIOP).

You can see that full pre-report here at BiohealthInvestor.com.  As always be advised that there may be new sets of data released between now and the actual meeting from May 29 to June 2, 2009 in Orlando, Florida.

Posted on: May 14, 2009 – 4:56 pm in Biotech, Drug companies, Medical, Pharmaceuticals, , , , , , , , , , , , , , , , , , ,

Weekend of Cancer Data at AACR Ahead of ASCO (ALTH, AMGN, ARIA, ARRY, AZN, BIIB, CELG, CRIS, IMMU, IMGN, INFI, MEDX, MNTA, ONCY, PFE, PCYC, SUPG, TELK, THLD)

This weekend will be a potentially important oncology and cancer news weekend for drug and biotech stocks.  The American Association for Cancer Research Meeting will actually have a 100th annual meeting, and some traders and investors may be using this as a preview for what lies ahead at the American Society of Clinical Oncology (ASCO) annual meeting in a month.  The following companies which are presenting data:

  • Allos Therapeutics, Inc. (NASDAQ: ALTH)
  • Amgen (NASDAQ: AMGN)
  • ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA)
  • Array BioPharma, Inc. (NASDAQ: ARRY)
  • AstraZeneca’s (NYSE: AZN) Medimmune unit
  • Biogen Idec Inc. (NASDAQ: BIIB)
  • Celgene Corporation (NASDAQ: CELG)
  • Curis, Inc. (NASDAQ: CRIS)
  • Immunomedics, Inc. (Nasdaq: IMMU)
  • ImmunoGen, Inc. (Nasdaq: IMGN)
  • Infinity Pharmaceuticals, Inc. (NASDAQ: INFI)
  • Medarex, Inc. (Nasdaq: MEDX)
  • Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA)
  • Oncolytics Biotech, Inc. (NASDAQ: ONCY)
  • Pfizer (NYSE: PFE)
  • Pharmacyclics, Inc. (NASDAQ: PCYC)
  • SuperGen Inc. (NASDAQ:SUPG)
  • Telik, Inc. (Nasdaq: TELK)
  • Threshold Pharmaceuticals, Inc. (Nasdaq: THLD)

You can see a full summary of the data being presented at BioHealthInvestor.com site.  There will be others presenting data this weekend, and these were from the press releases of the meeting ahead of time.

JON C. OGG

Posted on: April 17, 2009 – 2:05 pm in Biotech, Calendar, Drug companies, , , , , , , , , , , , , , , , , , ,

Top 10 Pre-Market Analyst Calls (ATVI, ALTH, BHI, BSC, GS, LEH, COO, CEPH, MRVL, TIF, PAY, XMSR)

These are not the only impact-calls affecting stocks from analysts in pre-market trading, but these are the ones that 24/7 Wall St. is focusing on:

  • Activision (ATVI) raised to Overweight at Lehman.
  • Allos Therapeutics (ALTH) started as Buy at Banc of America.
  • Baker Hughes (BHI) started as Buy at Oppenheimer.
  • Bear Stearns (BSC), Goldman Sachs (GS) & Lehman Bros. all downgraded to Sell from Market Perform at Punk Ziegel.
  • CNOOC Ltd. (COO) downgraded to Neutral from Outperform at Credit Suisse.
  • Cephalon (CEPH) raised to Outperform at FBR.
  • Marvell Tech (MRVL) reinitiated with coverage at Buy at Merrill Lynch.
  • Tiffany & Co. (TIF) downgraded to Neutral from Buy at Banc of America.
  • VeriFone (PAY) downgraded to Neutral at Merrill Lynch.
  • XM Satellite Radio downgraded to SELL at Goldman Sachs.

Jon C. Ogg
December 4, 2007

Posted on: December 4, 2007 – 8:09 am in Analyst Calls, , , , , , , , , , , ,

Short Selling Volatile Biotechs (June 2007) (DNDN, NFLD, NSTK, ADLR, ALTH, COLY, CEGE, NUVO)

Stock Tickers: DNDN, NFLD, NSTK, ADLR, ALTH, COLY, CEGE, NUVO

Many of the recent biotech implosions are always interesting to see if short sellers are getting out of the way or adding pressure.  Out of the biotechs we covered with recent implosions here is what we saw from May to June.  Oddly enough, only Dendreon (DNDN) out of this group showed a drop in the short interest out of this group from May to June..

Dendreon (DNDN)…can’t forget them. Recently we noted how options were weighing on the stock and how the company probably had a news vacuum coming up.
June Short Interest: 40.8 million shares, down almost 2% from May.
May Short Interest: 41.66M.

Adolor Corp. (ADLR)
June Short Interest: 6.5 million shares, up almost 10% from May.
May Short Interest: 5.9 million shares.

Allos Therapeutics (ALTH) didn’t implode, but it looked like it was going to.  Short sellers didn’t have the news ahead of time so maybe the short-covering was a savior.
June Short Interest: 5.17 million shares, up 30% from May.
May Short Interest: 3.97 million shares.

Northfield Labs (NFLD)….going, going, gone…..Biotech Zombie.
June Short Interest: 8.06 million shares, up 8% from May.
May Short Interest:  7.4 million shares.

Nastech Pharma (NSTK) was Cramer’s biotech zombie he said was looking up back in March. Short sellers bet against Cramer.
June Short Interest: 5.09 million shares, up 21% from May.
May Short Interest: 4.2 million shares.

Coley Pahrmaceuticals (COLY)….short sellers didn’t know this was getting the bad news at the cut-off date.
June Short Interest: 4.7 million shares, up 5% from May.
May Short Interest: 4.46 million shares.

Cell Genesys (CEGE)
June Short Interest: 15.4 million shares, up almost under 10% from May.
May Short Interest: 14 million shares.

Nuvelo Inc. (NUVO)…short sellers didn’t know for sure that Bayer was bailing here…..
June Short Interest: 8.06 million shares, up 8% from May.
May Short Interest: 7.44 million shares.

The Biotech HOLDRs (BBH) are hard to draw an inference to because of the size differentials and volume, but its June short interest was up more than 4% from May with a reading of 1.72 million shares.

Jon C. Ogg
June 27, 2007

Jon Ogg can be reached at jonogg@247wallst.com; he does not own securities in the companies he covers.

Posted on: June 27, 2007 – 12:36 pm in Biotech, Short Interest, , , , , , , ,

Pre-Market Stock News (June 19, 2007)

(ALTH) Allos Therapeutics trading down 20% after its Phase III study of Efaproxyn failed to meet primary endpoint of improvement in overall survival.
(BAY) Bayer raised guidance on Schering integration.
(BMY) Bristol-Myers: FDA Grants Priority Review for Bristol-Myers Squibb’s Investigational Oncology Treatment Ixabepilone.
(BTU) Peabody Energy was named Cramer’s favorite pick in the coal sector.
(CLRK) Color Kinetics trading up 11% at $33.00+ on $34 buyout from Philips Electronics.
(CPKI) California Pizza Kitchen trades ex-split today to reflect a 3-2 stock Split.
(CUB) Cubic received a $468 million contract to give mission support to Army readiness training center.
(DAL) Delta is considering a 125 Boeing order for Dreamliners.
(DJ) Dow Jones may get a bid from billionaire Ron Burkle.
(EXPE) Expedia buying back $3.5 Billion in stock.
(FDS) FactSet $0.52 EPS vs $0.51 estimate.
(GE) GE buying controlling stake in natural gas pipeline Regency for $603 million.
(INO) Inovio Biomedical’s selective electrochemical tumor ablation therapy demonstrated safety, tolerability, and complete responses in breast cancer study.
(LNET) LodgeNet noted positively by Cramer on Mad Money.
(MRO) Marathon Oil trades ex-split today to reflect a 2-1 stock split.
(PRGS) Progress Software $0.45 EPS vs $0.41e.
(STR) Questar trades ex-split to reflect a 2-1 stock split.
(SGMO) Sangamo BioScience reached milestones in agriculture collaboration with Dow AgroSciences.
(SIRI) SIRIUS signed Volkswagen as standard equipment on all Touareg, New Beetle, New Beetle Convertible, GTI, and GLI sales for the 2008 models.
(TASR) TASER announced foreign order for 1,375 devices.
(TSN) Tyson making product announcementthis morning.
(YHOO) Yahoo! trading up 8% after Semel stepped down as CEO and co-founder Jerry Yang came back as CEO; Semel remaining non-executive Chairman.
(ZGEN) ZymoGenetics entered a global collaboration pact with Bayer for development and commercialization of recombinant human thrombin.

Jon C. Ogg
June 19, 2007

Jon Ogg can be reached at jonogg@247wallst.com; he does not own securities in the companies he covers.

Posted on: June 19, 2007 – 7:11 am in Pre-Market Activity, , , , , , , , , , , , , , , , , , , , , , ,

Biotech Implosion: Allos Therapeutics (ALTH)

Allos Therapeutics, Inc. (ALTH-NASDAQ) is indicated down almost 20% in thin pre-market trading after it announced that top line results from ENRICH, the Company’s pivotal Phase III study of EFAPROXYN plus whole brain radiation therapy (WBRT) in women with brain metastases originating from breast cancer. The study failed to achieve its primary endpoint of demonstrating a statistically significant improvement in overall survival in patients receiving EFAPROXYN plus WBRT, compared to patients receiving WBRT alone.  All secondary efficacy endpoints also failed to achieve statistical significance.

Based on these results, Allos intends to discontinue the development of EFAPROXYN and focus on advancing the development of PDX (Pralatrexate), its novel antifolate currently under evaluation in a pivotal Phase 2 study in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

Allos has essentially no revenues and as of last quarter it had $75.8 million in cash and short term investments and about $6 million in total liabilities.  Before today’s drop the market cap was $370 million.  The good news is that the company is still in the running here with another product candidate and that it still has plenty of cash.  The bad news is that it is now  in a spot where it has only the hope of a one-hit wonder potentially and is still worth more than 4-times its liquidity after just blowing a Phase III trial.

Jon C. Ogg
June 19, 2007

Jon Ogg can be reached at jonogg@247wallst.com; he does not own securities in the companies he covers.

Posted on: June 19, 2007 – 6:54 am in Biotech,